DE60313344T2 - Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen - Google Patents
Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen Download PDFInfo
- Publication number
- DE60313344T2 DE60313344T2 DE60313344T DE60313344T DE60313344T2 DE 60313344 T2 DE60313344 T2 DE 60313344T2 DE 60313344 T DE60313344 T DE 60313344T DE 60313344 T DE60313344 T DE 60313344T DE 60313344 T2 DE60313344 T2 DE 60313344T2
- Authority
- DE
- Germany
- Prior art keywords
- pyridylmethyl
- combination
- vitamin
- phthalazine
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41317602P | 2002-09-24 | 2002-09-24 | |
| US413176P | 2002-09-24 | ||
| PCT/EP2003/010578 WO2004028542A1 (en) | 2002-09-24 | 2003-09-23 | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60313344D1 DE60313344D1 (de) | 2007-05-31 |
| DE60313344T2 true DE60313344T2 (de) | 2008-01-03 |
Family
ID=32043216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60313344T Expired - Lifetime DE60313344T2 (de) | 2002-09-24 | 2003-09-23 | Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20060128716A1 (enExample) |
| EP (1) | EP1545534B1 (enExample) |
| JP (1) | JP2006502195A (enExample) |
| KR (1) | KR20050074450A (enExample) |
| CN (1) | CN100372535C (enExample) |
| AT (1) | ATE359789T1 (enExample) |
| AU (1) | AU2003299065B2 (enExample) |
| BR (1) | BR0314647A (enExample) |
| CA (1) | CA2499738A1 (enExample) |
| CR (1) | CR7754A (enExample) |
| DE (1) | DE60313344T2 (enExample) |
| EC (1) | ECSP055700A (enExample) |
| ES (1) | ES2285251T3 (enExample) |
| HR (1) | HRP20050281A2 (enExample) |
| MX (1) | MXPA05003161A (enExample) |
| NO (1) | NO20051936L (enExample) |
| PL (1) | PL374696A1 (enExample) |
| PT (1) | PT1545534E (enExample) |
| RS (1) | RS20050228A (enExample) |
| RU (1) | RU2353364C2 (enExample) |
| WO (1) | WO2004028542A1 (enExample) |
| ZA (1) | ZA200502212B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE407683T1 (de) * | 1997-10-15 | 2008-09-15 | Polarx Biopharmaceuticals Inc | Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von multiplen myelom |
| WO2007030582A2 (en) | 2005-09-09 | 2007-03-15 | Bristol-Myers Squibb Company | Acyclic ikur inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132458B2 (en) * | 1994-08-10 | 2006-11-07 | Chemaphor Inc. | Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
| IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| RU2136308C1 (ru) * | 1994-11-16 | 1999-09-10 | Жемчугов Владислав Евгеньевич | Стимулятор роста костно-мозговых клеток человека |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CA2366857C (en) * | 1999-03-30 | 2010-12-14 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
| AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
| CA2393252A1 (en) * | 1999-12-06 | 2001-06-07 | Paul Calabresi | Use of methylol-containing compounds to treat tumors |
-
2003
- 2003-09-23 CA CA002499738A patent/CA2499738A1/en not_active Abandoned
- 2003-09-23 AU AU2003299065A patent/AU2003299065B2/en not_active Ceased
- 2003-09-23 RU RU2005112711/14A patent/RU2353364C2/ru not_active IP Right Cessation
- 2003-09-23 RS YUP-2005/0228A patent/RS20050228A/sr unknown
- 2003-09-23 PL PL03374696A patent/PL374696A1/xx not_active Application Discontinuation
- 2003-09-23 JP JP2004538994A patent/JP2006502195A/ja active Pending
- 2003-09-23 HR HR20050281A patent/HRP20050281A2/xx not_active Application Discontinuation
- 2003-09-23 DE DE60313344T patent/DE60313344T2/de not_active Expired - Lifetime
- 2003-09-23 MX MXPA05003161A patent/MXPA05003161A/es active IP Right Grant
- 2003-09-23 PT PT03798175T patent/PT1545534E/pt unknown
- 2003-09-23 WO PCT/EP2003/010578 patent/WO2004028542A1/en not_active Ceased
- 2003-09-23 ES ES03798175T patent/ES2285251T3/es not_active Expired - Lifetime
- 2003-09-23 US US10/528,914 patent/US20060128716A1/en not_active Abandoned
- 2003-09-23 EP EP03798175A patent/EP1545534B1/en not_active Expired - Lifetime
- 2003-09-23 CN CNB038227118A patent/CN100372535C/zh not_active Expired - Fee Related
- 2003-09-23 AT AT03798175T patent/ATE359789T1/de not_active IP Right Cessation
- 2003-09-23 BR BR0314647-2A patent/BR0314647A/pt not_active IP Right Cessation
- 2003-09-23 KR KR1020057004971A patent/KR20050074450A/ko not_active Ceased
-
2005
- 2005-03-16 ZA ZA200502212A patent/ZA200502212B/en unknown
- 2005-03-17 CR CR7754A patent/CR7754A/es not_active Application Discontinuation
- 2005-03-23 EC EC2005005700A patent/ECSP055700A/es unknown
- 2005-04-20 NO NO20051936A patent/NO20051936L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003299065B2 (en) | 2006-10-26 |
| JP2006502195A (ja) | 2006-01-19 |
| US20060128716A1 (en) | 2006-06-15 |
| ATE359789T1 (de) | 2007-05-15 |
| ECSP055700A (es) | 2005-08-11 |
| CN1684684A (zh) | 2005-10-19 |
| NO20051936L (no) | 2005-06-23 |
| RU2005112711A (ru) | 2006-02-27 |
| CR7754A (es) | 2005-12-02 |
| DE60313344D1 (de) | 2007-05-31 |
| PL374696A1 (en) | 2005-10-31 |
| WO2004028542A1 (en) | 2004-04-08 |
| ZA200502212B (en) | 2006-02-22 |
| CN100372535C (zh) | 2008-03-05 |
| ES2285251T3 (es) | 2007-11-16 |
| CA2499738A1 (en) | 2004-04-08 |
| HRP20050281A2 (en) | 2006-07-31 |
| BR0314647A (pt) | 2005-08-02 |
| EP1545534A1 (en) | 2005-06-29 |
| MXPA05003161A (es) | 2005-09-12 |
| EP1545534B1 (en) | 2007-04-18 |
| KR20050074450A (ko) | 2005-07-18 |
| RS20050228A (sr) | 2007-08-03 |
| AU2003299065A1 (en) | 2004-04-19 |
| RU2353364C2 (ru) | 2009-04-27 |
| PT1545534E (pt) | 2007-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60130017T2 (de) | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität | |
| DE60011391T2 (de) | Verfahren und zusammensetzungen zur erhöhung der anzahl weisser blutzellen | |
| DE69923322T2 (de) | Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung | |
| DE60037277T2 (de) | Adenosinrezeptor-agonist oder antagonist enthaltende pharmazeutische zusammensetzungen | |
| DE69530412T2 (de) | Zusammensetzung aus cisplatin in kombination mit 2,2'-dithio-bis(ethansulfonat)(dimesna) | |
| DE60037578T2 (de) | Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen | |
| DE60117615T2 (de) | Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen | |
| EP1037648B1 (de) | Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen | |
| DE69432644T2 (de) | Kombination eines Angiotensin-II antagonistisch wirkendes Benzimidazols mit ein Diuretikum | |
| DE60004348T2 (de) | Kombinierte vorbereitungen, die morpholin anthracyclin und platin derivate | |
| DE69309435T2 (de) | Restenosehemmer nach perkutaner koronarer arterioplastie | |
| CH686868A5 (de) | Infusionsloesung fuer die Verabreichung von Taxol. | |
| AT408414B (de) | Pharmazeutische kompositionen zum vorbeugen und heilen von krebserkrankungen und verfahren zu ihrer herstellung | |
| DE60124387T2 (de) | Synergistische pharmazeutische Zusammensetzungen zur Behandlung von kolorektalem Krebs | |
| DE69821498T2 (de) | Verwendung von amifostin | |
| DE3319347C2 (enExample) | ||
| DE60032517T2 (de) | Heilmittel gegen durch endothelin verursachte erkrankungen | |
| EP1765343A1 (de) | Verwendung von substituierten 2-thio-3,5-dicyano-4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen | |
| DE69632396T2 (de) | Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden | |
| DE60212710T2 (de) | Pharmazeutische zubereitungen enthaltend epothilone und deren verwendung bei der behandlung von karzinoid | |
| DE60313344T2 (de) | Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen | |
| EP2001555A1 (de) | Verwendung von strobilurinen zur behandlung von störungen des eisen-stoffwechsels | |
| DE68907976T2 (de) | Verwendung eines Thromboxan-A2-Rezeptorantagonist zur Herstellung eines Arzeneimittels zur Behandlung pulmonarer Hypertonie, die durch Protamin-induzierte Neutralisation von Heparin verursacht wird. | |
| DE60319211T2 (de) | Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs | |
| DE60200101T2 (de) | Kombination von acetyldinalin und docetaxel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |